NCT06716879View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

April 4, 2025

Study Completion Date

April 4, 2025

Conditions
Healthy Participants
Interventions
DRUG

Donzakimig

Drug: Donzakimig Pharmaceutical form: Subcutaneous solution

DRUG

Placebo

Drug: Placebo Pharmaceutical form: Subcutaneous solution

Trial Locations (1)

92801

UP0142 1, Anaheim

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT06716879 - A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants | Biotech Hunter | Biotech Hunter